Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza : to Develop Immunitas Therapeutics' Lead Drug Candidate in Tumors

04/15/2021 | 11:36pm EDT


© MT Newswires 2021
All news about LONZA GROUP AG
05/07LONZA  : Announces Results of the 2021 Annual General Meeting - All Motions Prop..
AQ
05/07LONZA  : Specialty Ingredients to Lift Prices of Selected Products Due to Rising..
MT
05/07LONZA  : Price Change Notification on Selected Product Portfolios
PU
05/07LONZA  : Moderna Expects No Impact of Possible Patent Waiver on COVID-19 Vaccine..
MT
05/07Switzerland Questions US Backing For Waiving COVID-19 Vaccine Patents
MT
05/06LONZA  : Switzerland Secures 14 Million Doses of Moderna's Booster COVID-19 Jab
MT
05/06Switzerland says U.S. stance on vaccine patent waiver leaves questions
RE
05/06Switzerland says U.S. announcement on vaccine patent waiver leaves questions
RE
05/06LONZA  : Moderna sees no impact on COVID-19 vaccine from potential patent waiver
RE
05/06GLOBAL MARKETS LIVE : Uber, AB Inbev, PayPal...
More news
Financials
Sales 2021 4 979 M 5 527 M 5 527 M
Net income 2021 1 039 M 1 153 M 1 153 M
Net Debt 2021 1 482 M 1 645 M 1 645 M
P/E ratio 2021 41,9x
Yield 2021 0,53%
Capitalization 42 891 M 47 533 M 47 609 M
EV / Sales 2021 8,91x
EV / Sales 2022 8,05x
Nbr of Employees 16 540
Free-Float 99,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 655,58 CHF
Last Close Price 577,40 CHF
Spread / Highest target 34,6%
Spread / Average Target 13,5%
Spread / Lowest Target -10,3%
EPS Revisions
Managers and Directors
NameTitle
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG1.51%47 533
MODERNA, INC.53.63%64 284
IQVIA HOLDINGS INC.30.82%44 316
CELLTRION, INC.-25.77%30 699
SEAGEN INC.-20.36%24 694
CUREVAC N.V.23.84%21 497